about
Pharmacokinetics of nicomorphine and its metabolites in man after epidural administrationEthylenediamine, profile of a sensitizing excipientCollecting data about drug use by elderly people.Data-reduction problems in biopharmaceutics and pharmacokinetics.Comparison of questionnaire information and pharmacy data on drug use.Pathophysiology of cytotoxic drug-induced emesis: far from crystal-clear.Controlling cancer chemotherapy-induced emesis. An update.Current status of interferon alpha in the treatment of chronic hepatitis B.Adverse effects of drugs on the blood.Drug transport across the blood-brain barrier. II. Experimental techniques to study drug transport.Antimicrobial screening of essential oils and extracts of some Humulus lupulus L. cultivars.Synthesis and radioreceptor binding activity of N-0437, a new, extremely potent and selective D2 dopamine receptor agonist.The risks of handling cytotoxic drugs. II. Recommendations for working with cytotoxic drugs.Pharmacokinetics of nalidixic acid in man: hydroxylation and glucuronidation.A drug use review study in patients with obstructive lung disease. Assessment of the quality of drug therapy.Acitretin (Neotigason). A review of pharmacokinetics and teratogenicity and hypothesis on metabolic pathways.Putative therapeutic applications of calmodulin antagonists.Dealing with sadness, madness and hostility. New psychotropic drug remedies for the future.Future developments in the pharmacotherapy of lung disease.Cardiovascular drugs.Future directions in antimicrobial chemotherapy.Immunomodulators. Future prospects.Delivery of hormones: some new concepts.New cytotoxic drugs and targets in oncology.Future prospects in antiviral therapy.New developments in the pharmacotherapy of inflammatory bowel disease.Catecholamines in critical care. The commonly used catecholamines: receptor and clinical profile, indications and dosages.Didanosine, a new antiretroviral drug. A review.Drug transport across the blood--brain barrier. I. Anatomical and physiological aspects.Differentiation between valproate-induced anticonvulsant effect, teratogenicity and hepatotoxicity. Aspects of species variation, pharmacokinetics, metabolism and implications of structural specificity for the development of alternative antiepileptiInfluence of co-medication on the metabolism of valproate.Pharmacokinetics of valproate in pregnancy: mother-foetus-newborn.Valproate hepatotoxicity syndrome: hypotheses of pathogenesis.Metabolism of valproate to hepatotoxic intermediates.Strategies for identifying and developing new anticonvulsant drugs.Pharmacological, toxicological and neurochemical effects of delta 2(E)-valproate in animals.Drug use in non-hospitalized children.Therapeutic decision making of physicians.Platinum antitumour agents: a review of (bio)analysis.Clinical and pharmaceutical aspects in acute poisoning.
P1433
Q28236092-DFB93A72-AC5D-4781-B127-722FCD3DDA0BQ28306583-8F7F1970-D858-46E3-9E94-089E4E7962D1Q30586788-21E8B8C8-0E33-41F4-9791-CE29DE94AD13Q31135507-132FE3FB-54C2-4B97-89E0-7133DD621EBFQ31172149-68FA3A82-CF3A-4A68-8F13-82B7EAAA1F9DQ33245513-A81CD947-974C-4931-B985-A0BEDDB9724CQ33284409-7F93242C-B8A0-48D9-AC5F-1BEFF4F62998Q33356343-832A7AA7-8109-4CCE-8788-1408E281AA81Q33480925-A6E548D7-5D0C-4F7F-87A8-2851E16018FFQ33975407-12C48ED2-7019-462D-9AC1-43E83EFE672FQ34293661-BB16A020-0D3A-414F-A700-29C7B8F5A131Q34562306-E9BBA836-2D01-4670-BC35-D2DE3E0E719AQ34624073-AC453EF5-7C5E-40F2-B8D3-DA371FBB91D6Q34686563-B54565F6-A5A3-45CC-BD70-FA072C9ADFA0Q35270813-49A868A2-FE16-4ED2-BC4C-0DE335606320Q35351720-7E4D60E5-7A6B-45D1-99A3-078B8B782C72Q35530681-045143F8-3325-448F-990F-C03CCD4D3ED3Q35530687-833519E3-B440-4807-BF8E-CBBB5BCE9A44Q35530694-885FA858-A8E6-4439-AD52-63AA7779BD57Q35530699-960EB887-22F7-466C-B35D-AE2608CC1A28Q35530705-52ADCFE3-4212-49D2-AEBA-604FDD9B0111Q35530709-741413D0-356B-4B34-BC4D-988AD0416C46Q35530712-4C9370C7-D098-4613-80D8-0D2C836EBB28Q35530717-BBA5A93C-24A1-44A3-8ACF-59864318235AQ35530722-082610ED-A95E-443F-B295-0321E70FC7FAQ35530728-F0C84036-E5C4-48D9-9944-48CD6BA68497Q35530734-1689F975-C562-4794-9002-A5BA047983C9Q35530740-64948886-8676-494F-8A4E-2DE45349DEF5Q35530747-2EB8C5AE-A288-4D28-8199-B9E10063C380Q35690870-63C68359-BEBD-47FD-843F-FBFC578705C3Q35690874-0FA67D4F-3EC5-4D28-A2F6-DE4FD3119053Q35690877-FA29FBCB-F1AC-4550-94A3-BCCD1CFB8FCAQ35690882-07DE4F2B-C671-40A2-AA64-32D40A50B671Q35690886-04832FC9-7316-40BA-B149-C824458F0312Q35690890-EC78F5C8-A71C-41D0-B523-6B438E2AD4CEQ35690895-93161293-EF69-47BC-A664-71BB8922B079Q35942796-0CFDB65C-23A9-49BE-8480-182D0CEEC86EQ35942801-1E2E0557-9E8B-413B-80BE-1EC93D452925Q36322728-CA7A3BB9-B764-4489-A47B-5494F3029BF8Q36322734-A408D63E-2466-4AA3-B76D-3DAC89978554
P1433
description
journal
@en
revista científica
@es
rivista scientifica
@it
wetenschappelijk tijdschrift van Springer Science+Business Media
@nl
wissenschaftliche Fachzeitschrift
@de
name
Pharmaceutisch weekblad. Scientific edition
@ast
Pharmaceutisch weekblad. Scientific edition
@en
Pharmaceutisch weekblad. Scientific edition
@es
Pharmaceutisch weekblad. Scientific edition
@it
Pharmaceutisch weekblad. Scientific edition
@nl
type
label
Pharmaceutisch weekblad. Scientific edition
@ast
Pharmaceutisch weekblad. Scientific edition
@en
Pharmaceutisch weekblad. Scientific edition
@es
Pharmaceutisch weekblad. Scientific edition
@it
Pharmaceutisch weekblad. Scientific edition
@nl
altLabel
Pharm Weekbl Sci
@en
prefLabel
Pharmaceutisch weekblad. Scientific edition
@ast
Pharmaceutisch weekblad. Scientific edition
@en
Pharmaceutisch weekblad. Scientific edition
@es
Pharmaceutisch weekblad. Scientific edition
@it
Pharmaceutisch weekblad. Scientific edition
@nl
P3181
P1055
P1156
P1476
Pharmaceutisch weekblad. Scientific edition
@en